Valneva SE
-
Ticker
Exchange
-
Industry
Biotechnology More
-
Sector
Healthcare More
- 201-500 Employees
- Based in Saint-Herblain, France
Valneva SE, a specialty vaccine company, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; and DUKORAL, an oral vaccine for the prevention
…More of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium. The company also develops VLA15, a vaccine candidate that is in Phase II clinical trial against Borrelia; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; and VLA2001, a vaccine candidate that has completed Phase I/II clinical trial against SARS-CoV-2. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. The company has collaborations with Pfizer to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. Valneva SE was incorporated in 1999 and is headquartered in Saint-Herblain, France.
REPORT RATINGS
5.0 / 5.0 (1)
Valneva SE reports have an aggregate usefulness score of 5.0 based on 1 reviews.
Valneva SE
Most Recent Responsibility Report
MOST RECENT
2023 Sustainability Report
Archived Responsibility Reports
Our service enables potential investors to review the most recent and archived Valneva SE Sustainability Report, Valneva SE Corporate Social Responsibility Report, Valneva SE CSR Report, Valneva SE Corporate Responsibility, Valneva SE CR Report, Valneva SE Citizenship Report, Valneva SE ESG Report, and Valneva SE Environmental Report online.